World Bipolar Day: How Vagus Nerve Stimulation and ZenoWell May Support Better Mental Health

March 30 marks World Bipolar Day and also the birthday of Vincent van Gogh. This coincidence offers more than a symbolic moment. It invites us to reflect on how we understand people living with bipolar disorder, how we talk about emotional suffering, and how we might develop new ways to support mental health with greater compassion and scientific precision.

Bipolar disorder is often reduced to the idea of “mood swings,” but this description misses the complexity of the condition. Bipolar disorder is a serious mood disorder characterized by recurrent episodes of mania or hypomania, depression, or mixed affective states. These episodes can affect sleep, energy, decision-making, impulse control, cognition, social functioning, and physical health. People with bipolar disorder often live not only with emotional instability, but also with stigma, delayed diagnosis, recurrent relapse, and a substantial burden on everyday life.

On a day dedicated to awareness, it is worth asking a forward-looking question:

Could transcutaneous auricular vagus nerve stimulation (taVNS) become a meaningful new avenue for supporting emotional regulation, autonomic balance, and overall mental health in people with bipolar disorder?

Seeing bipolar disorder beyond labels

Bipolar disorder is not simply a condition of “highs and lows.” During manic or hypomanic episodes, individuals may experience elevated or irritable mood, decreased need for sleep, increased goal-directed activity, impulsive spending, racing thoughts, and risk-taking behavior. During depressive episodes, they may experience low mood, anhedonia, fatigue, slowed cognition, hopelessness, and social withdrawal. Between episodes, many people continue to face residual symptoms, cognitive difficulties, and functional impairment.

Importantly, bipolar disorder is increasingly understood not only as a disorder of mood, but also as a disorder involving stress regulation, circadian instability, autonomic nervous system dysfunction, and possibly immune-inflammatory dysregulation. This broader systems perspective matters because it opens the door to new interventions that do more than target symptoms in isolation.

Emotional dysregulation, the vagus nerve, and autonomic imbalance

A growing body of research suggests that emotional regulation is deeply linked to the autonomic nervous system (ANS), especially the balance between sympathetic activation and parasympathetic, vagally mediated regulation. The vagus nerve plays a central role in this process. It is a major bidirectional communication pathway between the brain and the body, involved in heart rate regulation, stress recovery, inflammatory control, and emotional processing.

Recent reviews on vagus nerve stimulation have emphasized that vagal pathways may influence mental health through both ascending and descending mechanisms. On the ascending side, vagal afferents project to the nucleus tractus solitarius (NTS) and then influence brainstem and forebrain structures involved in arousal, attention, and emotion, including the locus coeruleus-norepinephrine (LC-NE) system. On the descending side, vagus nerve stimulation may engage the cholinergic anti-inflammatory pathway, modulating inflammatory signaling relevant to neuropsychiatric disorders (Zhang et al., 2026; Tyler, 2026).

This is particularly relevant for bipolar disorder because emotional dysregulation in BD is unlikely to be a purely psychological phenomenon. It may reflect a broader disturbance in how the brain and body coordinate arousal, recovery, and internal homeostasis.

What HRV research suggests about bipolar disorder

One useful window into autonomic function is heart rate variability (HRV), a non-invasive measure of beat-to-beat variation in heart rate. In general, higher HRV, especially indices linked to parasympathetic regulation, is associated with greater autonomic flexibility and resilience. Lower HRV is often interpreted as a sign of reduced vagal tone, impaired stress adaptability, and higher physiological burden.

An umbrella review of meta-analyses by Wang et al. (2025) found that HRV abnormalities are reported across many mental disorders, although the strength of evidence varies by condition and HRV metric. For bipolar disorder, the available evidence suggests autonomic dysregulation may be present, but the field still lacks highly consistent, high-certainty conclusions. In other words, there is a signal, but it remains underdeveloped and in need of more rigorous characterization.

More direct support comes from a study of non-medicated patients with bipolar disorder by Gupta et al. (2025). In that study, patients with bipolar disorder showed significantly reduced HRV compared with healthy controls across multiple domains. Time-domain indices such as SDNN, RMSSD, NN50, and pNN50 were lower. Frequency-domain changes included reduced high-frequency (HF) power and an increased LF/HF ratio, suggesting reduced parasympathetic influence and relative sympathetic dominance. Nonlinear HRV indices such as SD1, SD2, and approximate entropy were also reduced. The authors further reported that lower HRV tended to be associated with greater symptom severity, and that patients in manic states showed higher LF/HF ratios than those in depressive states (Gupta et al., 2025).

Taken together, these findings suggest that bipolar disorder may involve a pattern of:

• reduced vagal regulation
• increased sympathetic predominance
• lower autonomic flexibility
• state-dependent physiological dysregulation

This matters because if bipolar disorder includes a measurable autonomic phenotype, then interventions targeting vagal pathways may deserve closer attention.

Why taVNS is an interesting candidate

Transcutaneous auricular vagus nerve stimulation (taVNS) is a non-invasive neuromodulation technique that stimulates the auricular branch of the vagus nerve through specific regions of the external ear, such as the cymba conchae or tragus. Compared with implanted cervical vagus nerve stimulation, taVNS is more accessible, lower-cost, and easier to integrate into longitudinal care.

Its relevance to mental health lies in the fact that it may act on both brain and body systems.

1. Modulating arousal and emotional control networks

taVNS activates vagal afferent pathways that project to the NTS and can influence the LC-NE system, which is strongly implicated in arousal, vigilance, stress responsiveness, and affective regulation. Tyler (2026) argues that this mechanism may be particularly relevant for conditions marked by emotional dysregulation, hyperarousal, and chronic stress-related dysfunction, including depression, anxiety disorders, and PTSD.

Although bipolar disorder was not the central focus of that review, the same logic may apply. States of mania, irritability, agitation, and sleep disruption may involve altered arousal regulation, making vagal modulation conceptually relevant.

2. Supporting autonomic rebalance

Because HRV studies suggest reduced parasympathetic activity in bipolar disorder, taVNS may have potential to support autonomic rebalancing. If stimulation can increase vagal tone or improve vagally mediated HRV indices, it could theoretically help regulate physiological arousal alongside emotional instability. This possibility has particular appeal for bipolar disorder, where mood symptoms and bodily stress states often interact in powerful ways.

3. Influencing neuroimmune pathways

A second major theme in recent taVNS research is its role in inflammation regulation. Reviews by Zhang et al. (2026) and Tyler (2026) emphasize that vagus nerve stimulation may attenuate inflammatory responses through the cholinergic anti-inflammatory pathway, suppressing pro-inflammatory cytokines such as TNF-α and IL-6. These neuroimmune mechanisms have become increasingly relevant in psychiatric research, where inflammation is now viewed as part of the broader pathophysiological landscape of mood disorders.

If bipolar disorder involves not only emotional instability but also inflammatory and autonomic dysregulation, then taVNS may offer a systems-level intervention rather than a symptom-specific one.

What we know from depression research, and why it is not enough

One important reason for optimism comes from the depression literature. In a systematic review and meta-analysis of randomized controlled trials, Tan et al. (2023) found that taVNS significantly improved depressive symptoms and reduced Hamilton Depression Rating Scale scores. Their analysis suggested that taVNS may have higher response rates than sham stimulation and comparable response rates to antidepressants in some contexts, while also showing a favorable safety profile.

This is encouraging, but it does not mean the same evidence can simply be generalized to bipolar disorder. Bipolar depression is not identical to unipolar depression. Bipolar disorder includes risks of mood switching, mixed states, mania or hypomania, and greater heterogeneity in autonomic and circadian dysfunction. Any intervention that appears useful in depression must therefore be evaluated carefully and directly in bipolar populations.

At present, this is the central gap: there is growing enthusiasm for taVNS in depression and other neuropsychiatric disorders, but there is still a lack of direct clinical studies specifically testing taVNS in bipolar disorder.

A timely question for the future

On Bipolar Awareness Day, perhaps the most important message is not that we already have all the answers, but that we now have a better question.

If bipolar disorder involves emotional dysregulation together with measurable autonomic imbalance, could taVNS become a safe, non-invasive, and biologically informed tool to support mental health in this population?

Future research could begin to answer this by exploring:

• randomized controlled trials of taVNS in bipolar disorder
• phase-specific effects in mania, bipolar depression, and euthymia
• HRV as a biomarker of autonomic response
• inflammatory markers such as IL-6, TNF-α, and CRP
• safety, especially with respect to sleep, arousal, and risk of mood switching
• individualized stimulation parameters and treatment timing

These are not abstract academic questions. They are the kinds of questions that could shape future, more humane forms of care.

On this day, let awareness become connection

March 30 is a reminder to look beyond myth, beyond labels, and beyond the false simplicity of “highs and lows.” People living with bipolar disorder deserve research that takes the full complexity of their experience seriously. They deserve interventions that are not only effective, but also accessible, tolerable, and grounded in real mechanisms.

If you are interested in the intersection of bipolar disorder, taVNS, and mental health innovation, feel free to connect with us and continue the conversation. Stay tuned.

And on this Bipolar Awareness Day, let us continue to support mental health not only with words, but with curiosity, care, and science.

Bi-polar, never bi-alone.
Don’t stand at two poles — stand closer.

References:

1. Gupta, D., Kumar, C., Lal, M., Sunita, Kumar, M., Kumari, J., & Sinha, N. (2025). Heart Rate Variability in Non-Medicated Patients with Bipolar Disorder. European Journal of Cardiovascular Medicine, 15(2).
2. Tan, C., Qiao, M., Ma, Y., Luo, Y., Fang, J., & Yang, Y. (2023). The efficacy and safety of transcutaneous auricular vagus nerve stimulation in the treatment of depressive disorder: A systematic review and meta-analysis of randomized controlled trials. Journal of Affective Disorders, 337*, 37–49. https://doi.org/10.1016/j.jad.2023.05.048
3. Tyler, W. J. (2026). Transcutaneous Auricular Vagus Nerve Stimulation for Treating Emotional Dysregulation and Inflammation in Common Neuropsychiatric Disorders. Brain Sciences, 16(1), 8. https://doi.org/10.3390/brainsci16010008 Wang, Z., Zou, Y., Liu, J., Peng, W., Li, M., & Zou, Z. (2025). Heart rate variability in mental disorders: an umbrella review of meta-analyses. Translational Psychiatry, 15, 104. https://doi.org/10.1038/s41398-025-03339-x 
4. Zhang, X., Zou, Q., Zhang, J., Rong, P., & Wang, Y. (2026). Modulating neuroimmune function: The key in taVNS therapy for neurological and psychiatric disorders. Current Opinion in Pharmacology, 86, 102601. https://doi.org/10.1016/j.coph.2025.102601